Personalized Drug Selection for Pancreatic Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any other anti-cancer therapy, except for certain supportive care medications that were started at least one month before joining the study.
What data supports the effectiveness of this treatment for pancreatic cancer?
Research shows that using patient-derived models to test drug combinations can help identify personalized treatments for pancreatic cancer, as no single drug works for most patients. This approach has been effective in predicting which treatments might work best for individual patients, suggesting it could improve outcomes.12345
Is the personalized drug selection for pancreatic cancer safe for humans?
The research suggests that using patient-derived models and next-generation sequencing (NGS) can help predict drug toxicity, which is important for safety. In a study, software analysis of NGS data identified biomarkers linked to increased toxicity, which matched reported side effects in patients, indicating a potential for predicting and managing safety concerns.16789
How is the treatment using tumor models for pancreatic cancer different from other treatments?
This treatment is unique because it uses patient-derived models like xenograft mice and organoids to personalize therapy for pancreatic cancer, allowing doctors to test and select the most effective drugs for each individual patient, unlike standard treatments that are not tailored to the patient's specific tumor characteristics.17101112
What is the purpose of this trial?
The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.
Research Team
Robert C. Grant, MD
Principal Investigator
Princess Margaret Cancer Centre
Eligibility Criteria
This trial is for individuals with pancreatic cancer. It's exploring if using Patient Derived Organoids (PDO) to select a personalized drug treatment can be effective. Participants must have a type of pancreatic cancer that qualifies and should meet other specific health criteria not detailed here.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a drug selected based on their Patient Derived Organoids (PDO) results for either progressive disease or maintenance therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Using Tumor Models to Determine Treatments
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor